![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
449kB |
| Item Type: | Article |
|---|---|
| Title: | Sinusoidal obstruction syndrome following myeloablative therapy and tranexamic acid treatment for hemorrhage in two patients with neuroblastoma |
| Creators Name: | Zirngibl, F., Flemmig, C., Lang, P., Künkele, A., Eggert, A., Schulte, J.H. and Deubzer, H.E. |
| Abstract: | Adverse thromboembolic events following administration of the anti-fibrinolytic agent tranexamic acid (TA), used to prevent/treat excessive blood loss, are rare. We present the clinical course of two young patients (22 and 56 months) receiving busulfan/melphalan (Bu/Mel) high-dose chemotherapy with autologous hematopoietic stem cell transplantation (HSCT) to treat high-risk neuroblastoma, who developed hepatic sinusoidal obstruction syndrome (SOS) within 48 h after systemic TA treatment for a hemodynamically relevant hemorrhage. Defibrotide treatment resolved hepatic SOS, but the short time between TA administration and SOS onset suggests a causal association. |
| Keywords: | Pediatric Hematopoietic Stem Cell Transplantation, Embryonal Tumor, Transplant-Related Complication, Fibrinolysis Inhibitor, Thrombotic Event |
| Source: | Children |
| ISSN: | 2227-9067 |
| Publisher: | MDPI |
| Volume: | 7 |
| Number: | 11 |
| Page Range: | 198 |
| Date: | November 2020 |
| Official Publication: | https://doi.org/10.3390/children7110198 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
